Related Experiment Video
Updated: May 20, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal denervation: time to open Pandora's box
Yu-Mei Gu1, Kei Asayama, Yan-Ping Liu
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. maymaygu@hotmail.com
Swiss Medical Weekly
|July 20, 2012
Summary
Treatment-resistant hypertension affects 10-15% of patients. Renal denervation shows feasibility but requires more research for long-term effectiveness and safety in managing this condition.
Area of Science:
- Cardiology
- Nephrology
- Hypertension Management
Background:
- Treatment-resistant hypertension (TRH) prevalence ranges from 10% to 15%, often linked to conditions with increased sympathetic drive.
- Obesity, sleep apnea, diabetes, and renal dysfunction are associated with higher TRH rates.
Purpose of the Study:
- To evaluate the feasibility of intravascular renal denervation for TRH.
- To assess the antihypertensive, renal, and sympatholytic effects of renal denervation.
- To investigate long-term safety, quality of life, and cardiovascular-renal outcomes.
Main Methods:
- The study references the Symplicity trials, which employed intravascular renal denervation.
- Focus on assessing various efficacy and safety parameters post-procedure.
Main Results:
- Renal denervation was demonstrated as feasible in TRH patients.
- Conclusive evidence on the size, durability, and long-term impact of effects remains insufficient.
- Further data is needed on safety, quality of life, drug treatment relaxation, cost-effectiveness, and hard outcomes.
Conclusions:
- Renal denervation is feasible for TRH, but requires further investigation.
- The procedure should be limited to clinical research settings in specialized centers.
- Participation in independent international registries is recommended for comprehensive data collection.
